Wave Life Sciences (WVE) was not the only developer of RNA editing therapies to show significant stock gains from its historic proof-of-mechanism for its RNA editing platform, shown recently in the ...

WVE‑007 (GalNAc‑siRNA targeting Inhibin βE/Activin E) is being positioned to improve body composition—“become leaner, not lighter”—by reducing visceral fat while preserving muscle, with a Phase 2a ...

Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is ...

Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. GSK has given away rights to the most advanced RNA ...

Wave Life Sciences Ltd. (NASDAQ:WVE) stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 ...

Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. The company is generating ...

Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company specializing in RNA editing oligonucleotides, is navigating a complex landscape of genetic medicine development. With an InvestingPro ...

Chemistry optimization yields a four-fold increase over PBS control in AAT protein restoration in vivo preclinically (or more than 15 micromolar) CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- ...

We were the first to let you know about Vidar Hokstad’s Google Wave Gadget Emulator. Vidar has taken it a step further and now offers a full blown SVG editor that works in Wave’s ...